FDA Approves BUPRENORPHINE — INGENUS PHARMACEUTICALS, LLC

Ingenus Pharmaceuticals received FDA approval for the transdermal buprenorphine ANDA, a move that potentially disrupts the Integrated Pain Therapeutics (IPT) market by offering a preferred generic alternative that erodes that company's pricing power. The approval allows for a therapeutic comparison class that directly challenges IPT's sole-source product, placing significant competitive pressure on established revenues in this critical segment of the market.